Dejana Savic
$10/hr
Medical copywriter
- Reply rate:
- -
- Availability:
- Hourly ($/hour)
- Age:
- 37 years old
- Location:
- Kragujevac, Serbia, Serbia
- Experience:
- 5 years
Book Report: “Health economics with
Pharmacoeconomics for the students of
medical sciences; ISBN
978-86-7760-082-2"
Dejana M. Savić1*
1
w
e
i
v
Faculty of Medical Sciences Kragujevac, Serbia, Serbia
Submitted to Journal:
Frontiers in Pharmacology
e
r
In
Specialty Section:
Pharmaceutical Medicine and Outcomes Research
Article type:
Book Review Article
Manuscript ID:
190284
Received on:
07 Feb 2016
Frontiers website link:
www.frontiersin.org
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial
relationships that could be construed as a potential conflict of interest
Author contribution statement
D. Savić: Conception and design, writing the article, critical revision of the article, final approval of the article abd overall
responsibility.
w
e
i
v
Keywords
healyh economics, Pharmacoeconomics, textbook, Students, Medical, Western Balkans
e
r
In
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
Book Report:
“Health economics with Pharmacoeconomics for the students of
medical sciences; ISBN 978-86-7760-082-2"
Dejana Savic
Faculty of Medical Sciences University of Kragujevac Serbia
I have been honored by privilege of presenting a new university textbook written in
Serbian language entitled: "Health Economics and Pharmacoeconomics for the Students of
Medical Sciences", Edited by Prof Mihajlo (Michael) Jakovljevic MD, PhD (Jakovljevic,
2014). This book was authored by 38 leading experts in their respective fields, based in
South-Eastern Europe. Participation of governmental, academic and industrial sectors
among the authors of chapters helped to provide overview of major health economics issues
from a variety of aspects. This book is an ambitious pioneer project in creating university
textbook for postgraduate students in this field in native Balkan languages. Hereby I will
provide a short description of major topics covered by the Book content.
Since the early 1990s vast enchantments have been made in the field of health
economic research and clinical management of various entities from the group of prosperity
diseases in South-Eastern Europe (SEE). As prime examples could serve diabetes (Biorac,
2009), cancer (Kovacevic, 2015), risky pregnancies (Jakovljevic, 2008), addiction disorders
(Jakovljevic, 2014), hepatitis infections (Jakovljevic, 2013), community-acquired pneumonia
(Cupurdija, 2015), chronic obstructive pulmonary disease (Lazic, 2012), major depression
(Jakovljevic, 2015) and many others. Contribution of regional researchers in the field of
developing and implementing new healthcare technologies with utmost budget impact such
as monoclonal antibodies (Jakovljevic, 2014), radiology imaging procedures (Rankovic,
2013), radiation oncology treatments (Jakovljevic, 2014) and terminal palliative care
procedures (Kovacevic, 2015) should not be neglected. Some of the prominent money saving
procedures proved to be clinical dentistry (Rancic, 2015), generic replacement of brand name
medicines (Jakovljevic, 2014) and physician education (Vukovic, 2015) which showed the
greatest overall success. Persistent problems in financial sustainability of health sectors
related to population aging(Ogura, 2014) and prosperity diseases (Dagovic, 2015) in SEE
countries were fully identified and presented. Special attention is also directed to
pharmaceutical market evolution (Jakovljevic, 2015) as well as the issue of global health care
challenges due to the rise of top tier emerging markets (Jakovljevic, 2014), (Jakovljevic,
2015), (Jakovljevic, 2015).
This textbook has at first been intended for use by undergraduate students of
medicine, pharmacy and dentistry. However it turned out to be of an immense practical use
also for postgraduate master and PhD students of interdisciplinary health sciences due to its
comprehensive interdisciplinary reach. Due to its lingual limitations this textbook is of use
only in areas of mostly mutually understandable Western Balkan languages: Serbian,
Slovenian, Croatian, Bosnian and Macedonian. This textbook should be considered as highly
recommendable for studying and research by students of most private-owned and stateowned universities and other higher education establishments throughout former Yugoslavia
region.
The Book consists of 68 chapters (631 pages) organized in five consecutive sections.
General Part presents introduction to the concepts and definition of healthcare economics. I
Its historical development and terminology of the discipline is presented in further exposé.
The second, Special Part exposes the problematics of cost-of-illness studies as seen by a
variety of leading clinical medicine experts familiar with the respective fields. Several
e
r
In
w
e
i
v
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
chapters consider health care budget impact of some of the most costly medical interventions.
Consecutive Pharmacoeconomics Part is presented in form of detailed and elaborated
discussion about different methodological approaches ranging from cost-effectiveness
assessments to resource allocation analysis. Conclusive Remarks describe and elaborate the
emerging markets and provide quite realistic picture of the expected developments among the
Global and Eastern European/SEE health care markets. Fifth part is formed as the Book of
Terms, Index and comprehensive English/Serbian vocabulary of essential standardized and
broadly used international terms in disciplines of health economics and health policy. This
segment of the project should be of immense value for regional health economists and policy
makers understanding these topics and dealing with them in every day routine. Consensus of
vast variety of professionals of the respective fields is expected to diminish presumed lingual,
semantic and lexical difficulties that arise from diverse variations in translation of Englishborn notions to the Western Balkan languages.
As to be concluded on presented material, it is clear that this challenging endeavour
was performed in line with high academic standards and principles of good editorial practice.
The textbook entitled: „Health Economics with Pharmacoeconomics for the Students of
Medical Sciences will certainly be of use for generations of graduate and PhD students as
well as the teaching staff and research communities of the Western Balkans region.
Combined efforts of broad spectrum of professionals from academia, industry and national
authorities have greatly contributed to the Book's quality and its comprehensive reach.
Energized developments in health care economics are induced by the emerging Eastern
European markets undergoing end stages of transitional health reforms (Jakovljevic, 2013).
Such changes in health care financing, provision and management patterns will inevitably
affect academic aspects of health care economics. This landscape implicates requirement for
new knowledge to cope with the upcoming challenges (Jakovljevic, 2016), (Jakovljevic,
2015), (Jakovljevic, 2015). This pioneering achievement in academic health economics of
SEE region might serve as a prototype for future Endeavour of a kind.
w
e
i
v
e
r
In
Acknowledgements:
The Ministry of Education Science and Technological Development of the Republic of Serbia
has funded the underlying field studies behind reported results in the aforementioned
Textbook through Grant OI 175014. Publication of results was not contingent to Ministry’s
censorship or approval.
References:
1. Jakovljevic M et al, Health Economics and Pharmacoeconomics for the students of
medical sciences” , ISBN 978-86-7760-082-2 ; Publisher : Faculty of Medical
Sciences University of Kragujevac, Serbia 2014 [COBISS.SR-ID 207514636]
2. Biorac, N., Jakovljević, M. B., Stefanović, D., Perović, S., & Janković, S. (2009).
Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia.
Vojnosanitetski pregled, 66(4), 271-276.
3. Kovacevic A, Dragojevic-Simic V, Tarabar D, Rancic N, Jacimovic N, Katic J,
Dagovic A & Jakovljevic M, Five-year survival and costs of care in metastatic
colorectal cancer: conventional vs. monoclonal antibody - based treatment protocols,
Expert Review of Anticancer Therapy, Posted online on June 18, 2015. (Online) , 31
Jul 2015 (Print) (DOI:10.1586/14737140.2015.1059280)
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
4. Jakovljevic, M., Varjacic, M., & Jankovic, S. M. (2008). Cost‐Effectiveness of
Ritodrine and Fenoterol for Treatment of Preterm Labor in a Low–Middle‐Income
Country: A Case Study. Value in Health, 11(2), 149-153.
5. Jakovljevic M, Jovanovic M, Rancic N, Vyssoki B, Djordjevic N (2014) LAT
Software Induced Savings on Medical Costs of Alcohol Addicts' Care - Results from
a Matched-Pairs Case-Control Study. PLoS ONE 9(11): e111931.
doi:10.1371/journal.pone.0111931
6. Jakovljevic M, Miјailovic Z, Popovska Jovicic B, Canovic P, Gajovic O, Jovanovic
M, Petrovic D, Milovanovic O, Djordjevic N. Assessment of viral genotype impact to
the cost-effectiveness and overall costs of care for peg-Interferon-2α + ribavirine
treated chronic hepatitis C patients, Hepatitis Monthly, 2013;13(5):e6750. DOI:
10.5812/hepatmon.6750 2013.
7. Cupurdija, V., Lazic, Z., Mestrovic, M., Mojsilovic, S., Cekerevac, I., Rancic, N., &
Jakovljevic, M. (2015). Community-acquired pneumonia: economics of inpatient
medical care vis-à-vis clinical severity. Jornal Brasileiro de Pneumologia, 41(1), 4857.
8. Lazic Z, Gajovic O, Tanaskovic I, Milovanovic D, Atanasijevic D, Jakovljevic M.
GOLD Stage Impact on COPD Direct Medical Costs in Elderly. Health Behav & Pub
Health 2012 2(3): 1-7
9. Jakovljevic M, Tetsuji Y, Chia Ching C, Stevanovic D, Jovanovic M, Nikic Djuricic
K, Rancic N, Savic D, Biorac N, Mihajlovic G, Jankovic S, Cost–Effectiveness of
Depressive Episode Pharmacological Treatment, Hospital Pharmacology. 2015;
2(1):235-245
10. Jakovljevic, M., Gutzwiller, F., Schwenkglenks, M., Milovanovic, O., Rancic, N.,
Varjacic, M. & Matter-Walstra, K. (2014). Costs differences among monoclonal
antibodies-based first-line oncology cancer protocols for breast cancer, colorectal
carcinoma and non-Hodgkin’s lymphoma. J BUON, 19(3), 1111-20.
11. Ranković, A., Rančić, N., Jovanović, M., Ivanović, M., Gajović, O., Lazić, Z.,
&Jakovljević, M. (2013). Impact of imaging diagnostics on the budget: are we
spending too much?. Vojnosanitetski pregled, 70(7), 709-711.
12. Jakovljevic, M., Zugic, A., Rankovic, A., & Dagovic, A. (2014). Radiation therapy
remains the key cost driver of oncology inpatient treatment. Journal of medical
economics, 18(1), 29-36.
13. Kovačević, A., Dragojević-Simić, V., Rančić, N., Jurišević, M., Gutzwiller, F.,
Matter-Walstra, K., & Jakovljević, M. (2015). End-of-life costs of medical care for
advanced stage cancer patients. Vojnosanitetski pregled, 72(4), 334-341.
14. Rančić, J., Rančić, N., Majstorović, N., Biočanin, V., Milosavljević, M., &
Jakovljević, M. (2015). Cost differentials of dental outpatient care across clinical
dentistry branches. Farmeconomia. Health economics and therapeutic pathways,
16(1), 25-32.
15. Jakovljevic, M. B., Nakazono, S., & Ogura, S. (2014). Contemporary generic market
in Japan-key conditions to successful evolution. Expert review of pharmacoeconomics
& outcomes research, 14(2), 181-194.
16. Vuković, M., Gvozdenović, B. S., Ranković, M., McCormick, B. P., Vuković, D. D.,
Gvozdenović, B. D., ... & Jakovljević, M. B. (2015). Can Didactic Continuing
Education Improve Clinical Decision Making and Reduce Cost of Quality? Evidence
From a Case Study. Journal of Continuing Education in the Health Professions, 35(2),
109-118.
e
r
In
w
e
i
v
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
17. Ogura S, Jakovljevic M, Health financing constrained by population aging - an
opportunity to learn from Japanese experience, Ser J Exp Clin Res 2014; 15 (4): 175181 DOI: 10.2478/SJECR 2014 002
18. Dagovic, A., Zugic, A., & Jakovljevic, M. B. (2015). Macroeconomic Policy Impact
On Oncology-Related Public Expenditure In An Emerging European Market–Signs
Of Early Recovery. Serbian Journal of Experimental and Clinical Research, 16(1), 4350.
19. Jakovljevic M, Djordjevic N, Jurisevic M, Jankovic S, Evolution of Serbian
pharmaceutical market alongside socioeconomic transition, Expert Rev.
Pharmacoecon. Outcomes Res. Posted online on January 16, 2015.
(doi:10.1586/14737167.2015.1003044)
20. Jakovljevic M, The key role of leading emerging BRIC markets for the future of
global health care, SJECR, UDK: 614.2(100) / Ser J Exp Clin Res 2014; 15 (3): 139143.
21. Jakovljevic MB (2015) BRIC’s growing share of global health spending and their
diverging pathways. Front. Public Health 3:135. doi: 10.3389/fpubh.2015.00135
22. Jakovljevic M, Milovanovic O, (2015) Growing burden of non-communicable
diseases in the emerging health markets: the case of BRICS; Research Topic: Health
Care Financing and Affordability in the Emerging Global Markets, Front. Public
Health | doi: 10.3389/fpubh.2015.00065
23. Jakovljevic, M. B. (2013). Resource allocation strategies in Southeastern European
health policy. The European Journal of Health Economics, 14(2), 153-159.
24. Jakovljevic M, Groot W, Souliotis K, Health care financing and affordability in the
emerging global markets, Frontiers in Public Health, January 2016, DOI:
10.3389/fpubh.2016.00002
25. Jakovljevic M, Vukovic M, Fontanesi J, Life Expectancy and Health Expenditure
Evolution in Eastern Europe - DiD and DEA analysis, Expert Reviews in
Pharmacoeconomics and Outcomes research, December 2015,
DOI:10.1586/14737167.2016.1125293
26. Jakovljevic M, Comparison of Historical Medical Spending Patterns among the
BRICS and G7, Journal of Medical Economics, September 2015. DOI:
10.3111/13696998.2015.1093493
e
r
In
w
e
i
v
